Title:Oteseconazole: First Approved Orally Bioavailable and Selective
CYP51 Inhibitor for the Treatment of Patients with Recurrent
Vulvovaginal Candidiasis
Volume: 30
Issue: 37
Author(s): Surya K. De*
Affiliation:
- Conju-probe, San Diego, California, USA
- Department of Chemistry, Bharath University, Chennai, Tamil
Nadu, 600126, India
Keywords:
Antifungals, mechanism of action, fungal lanosterol demethylase, vaginitis, sterol biosynthesis, oteseconazole.
Abstract: Oteseconazole was approved by the US FDA in April 2022. It is the first approved
selective and orally bioavailable CYP51 inhibitor for the treatment of patients with
recurrent Vulvovaginal candidiasis. Herein, we describe its dosage, administration, chemical
structure, physical properties, synthesis, mechanism of action, and pharmacokinetics.